Q9T Stock Overview
A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ME Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.40 |
| 52 Week High | CA$2.68 |
| 52 Week Low | CA$0.50 |
| Beta | 0 |
| 1 Month Change | -4.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 367.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| Q9T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.2% | 0.7% | -0.8% |
| 1Y | n/a | -23.9% | 3.2% |
Return vs Industry: Insufficient data to determine how Q9T performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how Q9T performed against the German Market.
Price Volatility
| Q9T volatility | |
|---|---|
| Q9T Average Weekly Movement | 71.3% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: Q9T has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine Q9T's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Salim Dhanji | www.metherapeutics.com |
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate is a novel antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
ME Therapeutics Holdings Inc. Fundamentals Summary
| Q9T fundamental statistics | |
|---|---|
| Market cap | €79.15m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs Q9T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Q9T income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did Q9T perform over the long term?
See historical performance and comparison